Form 4: Monopar Therapeutics CEO Exercises Options, Sells Shares

Sentiment:

Insider Transaction Report 16 July 2025 9:02 PM

Monopar Therapeutics CEO and Director Chandler Robinson exercised stock options and subsequently sold 16,800 shares of common stock for approximately $40.00 per share.

Worse than expectedThe sale of 16,800 shares by the CEO and Director, Chandler Robinson, could be perceived negatively by investors as it might suggest a lack of confidence or a belief that the stock is fully valued.

Summary

Chandler Robinson, Chief Executive Officer and Director of Monopar Therapeutics (MNPR), completed two transactions on July 14, 2025.
Exercised stock options to acquire 16,800 shares of common stock at an exercise price of $0.005 per share.
Sold the same 16,800 shares at a weighted average price of $40.0012 per share, with individual sales ranging from $40.00 to $40.25.
Following these transactions, direct beneficial ownership stands at 73,472 shares.
Indirectly beneficially owns 822,255 shares through Tactic Pharma LLC, where Dr. Robinson is a manager, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of shares by the CEO, even following an option exercise, can be viewed as a slightly negative signal by the market, potentially indicating that the insider believes the stock is adequately valued or that they are taking profits.

Positives

The exercise of stock options indicates that the shares were significantly in-the-money, reflecting a substantial increase in value from the grant price.
The sale at $40.0012 per share represents a significant financial gain for the reporting person on the exercised options.

Negatives

The sale of 16,800 shares by a key insider (CEO and Director) could be interpreted by the market as a negative signal regarding future prospects or valuation.

Future Outlook

Industry Context

Related Party Transactions

Dr. Robinson's indirect beneficial ownership of 822,255 shares through Tactic Pharma LLC, where he is a manager, represents a related party interest. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

Shareholders: The sale by a key insider might lead to concerns about the company's future prospects or valuation, potentially impacting investor sentiment and share price.

Key Dates

Date	Description
02/20/2017	Date stock options were granted to Dr. Robinson.
07/14/2025	Date of stock option exercise and subsequent sale of shares.
07/16/2025	Date the Form 4 was signed.
02/20/2027	Expiration date of the exercised stock options.

Recommendation

hold

Keywords

Monopar Therapeutics, MNPR, SEC Form 4, insider trading, stock options, share sale, CEO, director, beneficial ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.